Hainan Kangzhi Pharmaceutical Co., Ltd. is located in the picturesque Hainan Province, covering an area of 160 acres, is one of the fastest growing, most efficient and largest pharmaceutical enterprises in Hainan Province in recent years, and is a key hi-tech enterprise of the National Torch Plan. on May 26, 2010, it was successfully listed on the Shenzhen Stock Exchange under the stock code of 300086, and became the first pharmaceutical enterprise listed on GEM board in Hainan Province. The company has established the principle of "Being a pharmaceutical company". The company has established the business strategy of "doing pharmaceutical products, doing professional market", focusing on children's health and building a national brand as the company's strategic goal.
The company has two production bases, including cephalosporin and penicillin solid preparation workshop, powder injection workshop and oral liquid workshop, *** seven dosage forms and ten production lines. The company has 5 international most advanced granule automated production lines with an annual production capacity of 2 billion bags, which is the largest production capacity and the highest degree of automation of granule production line in Asia.
Kangzhi pioneered the specialized cooperative agency marketing model, established a flat sales network platform, and with the business philosophy of "in-depth marketing, integration and multi-win", created a marketing team with professionalism and practical experience, and set up a marketing network that includes more than 1,000 agents and more than 30,000 sales terminals. The company has established a marketing network that includes more than 1,000 agents and over 30,000 sales terminals, and is firmly occupying the commanding heights of the primary care market.
Kangzhi attaches great importance to the research and development of new products and technologies, and has established technical platforms, including: drug synthesis laboratory, drug analysis laboratory, drug preparation laboratory, traditional Chinese medicine extraction and separation laboratory, and pilot plant, etc., and has established long-term technical cooperation with domestic famous universities and scientific research institutions.
The company adheres to the enterprise tenet of "Sincerity and Goodness in Medicine, Benefiting Humanity", which is sincerely interpreted in the business practice. "Sincere, caring and innovative" Kangzhi people are willing to sincerely cooperate with all colleagues in the pharmaceutical industry who are committed to the cause of children's health, and make continuous efforts for the health of mankind hand in hand.
Approved by the China Securities Regulatory Commission on May 4, 2010 "Securities Supervision and Administration License [2010] No. 549", the Company issued 25 million ordinary shares of RMB on May 13, 2010, and on May 26, 2010, it was listed on the Shenzhen Stock Exchange.